SCHEMBL13424415

SCHEMBL13424415

CC(C)(C)[Si](C)(C)O[C@H]1CC(CO)[C@H](OCc2ccccc2)[C@@H](OCc2ccccc2)C1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.38
SLC6A2 P23975 2/20 0.38
PDPK1 O15530 1/20 0.37
MTOR P42345 1/20 0.37
BCHE P06276 2/20 0.36
ACHE P22303 1/20 0.36
SLC5A1 P13866 1/20 0.33
SLC5A2 P31639 1/20 0.33
TACR1 P25103 1/20 0.33
RECQL P46063 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
KMT2A Q03164 1/20 0.33
PTPN1 P18031 1/20 0.32
CDC25B P30305 1/20 0.32
SSTR1 P30872 1/20 0.32
SSTR2 P30874 1/20 0.32
SSTR4 P31391 1/20 0.32
SSTR3 P32745 1/20 0.32
SSTR5 P35346 1/20 0.32
KLK7 P49862 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13424413 0.88 BCHE (0.36) PDE4DSLC6A2PDPK1MTORBCHE
SCHEMBL13424419 0.84 BCHE (0.38) PDE4DPDPK1MTORBCHEACHE
SCHEMBL25084017 0.82 BCHE (0.47) PDE4DSLC6A2PDPK1MTORBCHE
SCHEMBL14957939 0.80 BCHE (0.40) PDE4DBCHEACHESSTR1SSTR2
SCHEMBL4895151 0.77 CTSL (0.36) BCHEACHE
SCHEMBL14107809 0.77 CTSL (0.36) BCHEACHE
SCHEMBL4893196 0.75 CTSL (0.37) PDE4DSLC6A2BCHE
SCHEMBL14107808 0.75 CTSL (0.37) PDE4DSLC6A2BCHE
SCHEMBL22821467 0.75 SLC6A2 (0.34) PDE4DSLC6A2
SCHEMBL14958147 0.75 BCHE (0.36) PDE4DBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299223-B2 Pseudoglycolipid and use thereof RIKEN (JP) 2012-10-30 US disclosed
US-20100062990-A1 NOVEL PSEUDOGLYCOLIPID AND USE THEREOF RIKEN (JP) 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062990-A1 NOVEL PSEUDOGLYCOLIPID AND USE THEREOF PNLIP, SGMS1, SGPL1 PDE4D 2944/4885SLC6A2 2300/4885PDPK1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.